**Name of journal:** **World Journal of Gastroenterology**

**ESPS Manuscript NO: 11558**

**Columns: Topic Highlights**

WJG 20th Anniversary Special Issues (3): Inflammatory bowel disease

**Ulcerative colitis-associated colorectal cancer**

Yashiro M. colitic cancer

Masakazu Yashiro

**Masakazu Yashiro,** Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan

**Masakazu Yashiro,** Oncology Institute of Geriatrics and Medical Science, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan

**Author contributions:** Yashiro M solely contributed to the manuscript.

**Correspondence to: Masakazu Yashiro, MD, PhD,** Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. m9312510@med.osaka-cu.ac.jp

**Telephone:** +81-6-66453838  **Fax:** +81-6-66466450

**Received:** May 27, 2014 **Revised:** September 15, 2014

**Accepted:** October 14, 2014

**Published online:**

**Abstract**

The association between ulcerative colitis (UC) and colorectal cancer (CRC) has been acknowledged. One of the most serious and life threatening consequences of UC is the development of CRC (UC-CRC). UC-CRC patients are younger, have more frequently multiple cancerous lesions, and histologically show mucinous or signet ring cell carcinomas. The risk of CRC begins to increase 8 or 10 years after the diagnosis of UC. Risk factors for CRC with UC patients include young age at diagnosis, longer duration, greater anatomic extent of colonic involvement, the degree of inflammation, family history of CRC, and presence of primary sclerosing cholangitis. CRC on the ground of UC develop from non-dysplastic mucosa to indefinite dysplasia, low-grade dysplasia, high-grade dysplasia and finally to invasive adenocarcinoma. Colonoscopy surveillance programs are recommended to reduce the risk of CRC and mortality in UC. Genetic alterations might play a role in the development of UC-CRC. 5-aminosalicylates might play an important role in chemoprevention of CRC.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** ulcerative colitis-associated colorectal cancer; risk factors; Dysplasia; Surveillance colonoscopy; Chemoprevention

**Core tip:** Colorectal cancer (CRC) is increased in patients with long-term ulcerative colitis (UC), and is one of the most serious and life threatening consequences of UC. Knowledge of risk factor for CRC is important to determine UC patients who need surveillance. Colonoscopy surveillance programs are recommended to reduce the risk of CRC and mortality in UC. Genetic alterations might play a role in the development of CRC in UC patients. Five-aminosalicylates might play an important role in chemoprevention of CRC.

Yashiro M. Ulcerative colitis-associated colorectal cancer. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

Ulcerative colitis (UC) is a chronic inflammatory bowel disease showing mucosal inflammation from the rectum to oral side. Crohn and Rosenberg reported the first case of adenocarcinoma complicating UC in 1925[1]. Then, the risk of developing colorectal cancer (CRC) is found to be high in patients with long-term UC[2,3]. UC-CRC is considered to develop from a non-neoplastic inflammatory epithelium to dysplasia to cancer. Therefore, colonoscopic surveillance in patients with long-standing UC has been recommended. UC-CRC shows characteristic clinicopathological features of CRC. In this paper, the characteristic properties of UC-CRC are reviewed.

**CLINICAL FEATURES OF COLITIS-ASSOCIATED CRC**

***Clinicopathological features***

UC-CRC patients are younger, have more frequently multiple cancerous lesions, and a macroscopically permeating pattern of spread including mucinous or signet ring cell carcinomas, in comparison to sporadic CRC[[1-3](#_ENREF_1)]. The advanced stage at presentation causes less favorable outcome of UC-CRC in IBD patients.

***Incidence of UC-CRC***

An inflammatory environment is believed to play an important role for the pathogenesis of UC-CRC in patients with chronic colitis[[4](#_ENREF_4)]. UC-CRC accounts for about 1% of all CRC[[5](#_ENREF_5)]. The risk of CRC begins to increase 8 or 10 years after the initial diagnosis[[6-8](#_ENREF_6)]. Table 1 summarized representative reports about the risk of developing colorectal cancer in patients with UC. Eaden *et al*[[9](#_ENREF_9)] conducted a meta-analysis of 116 studies, and found that the probability of CRC in patients with UC is increasing as the duration of disease; 1.6% at 10 years after a onset of UC, 8.3% at 20 years after, and 18.4% at 30 years after. This increased incidence of UC-CRC is 4 to10 times greater than that for sporadic CRC, and the average age of onset is 20 years earlier. Other several studies reported that the risk for UC-CRC in UC patients was reported to be around 5%-7% at 20 years after onset of disease[[10-14](#_ENREF_10)], 7%–14% at 25 years[[15](#_ENREF_15),[16](#_ENREF_16)] and 7.5%-18%[[9](#_ENREF_9),[17](#_ENREF_17)] at 30 years. Eaden *et al*[[9](#_ENREF_9)] confirmed that there is an increased risk for UC-CRC in pancolitis (5.4%), while the incidence in all patient with UC was 3.7%. In some countries, patients with UC have not been found to be at increased risk of CRC development. Winther *et al*[[18](#_ENREF_18)] reported that the probability of CRC in Denmark was 0.4% by 10 years, 1.1% by 20 years, and 2.1% by 30 years of disease, suggesting that neither the overall cancer risk nor the UC-CRC risks were increased after a median of 19 years of follow-up evaluation. This low rate of CRC development may be due to the high rates of surgical approach and chemoprevention for UC in Denmark. Taken together, the 5-aminosalicylic acid (5-ASA) treatment and the frequent surveillance colonoscopy with proctocolectomy for dysplasia could explain the reduction in the incidence of CRC in UC patients. Moreover, current studies indicate that the risk of CRC seems to be lower. Rutter and co-workers reported cumulative incidences of UC-CRC of 2.5% at 20 years of colitis duration, 7.6% at 30 years, and 10.8% at 40 years[[19](#_ENREF_19)] indicating only a 1.5 to 2-fold increased risk for CRC (5%) in comparison with the non-UC population. Soderlund *et al*[[20](#_ENREF_20)] indicates that the overall cumulative incidence of CRC at 10, 20, and 30 years after the inflammatory bowel disease (IBD) diagnosis was 1%, 1.5%, and 2.7%, respectively. Manninen *et al*[[21](#_ENREF_21)] reported that an only slightly increased risk for UC-CRC in UC patients in Finland cohort. Hata *et al*[[22](#_ENREF_22)] reported that the cumulative risk for the development of invasive cancer at 10, 20, and 30 years was 0.5%, 4.1%, and 6.1%, respectively, while that for the development of definite dysplasia at 10, 20, and 30 years was 3.1%, 10.0%, and 15.6%, respectively. A further current systematic review with meta-analysis in 2014 based on81 studies and on 181923 patients reported that the risk of patients with UC developing colorectal cancer has decreased steadily, and the incidence rate decreased from 4.29/1000 patient-years in the 1950s to 1.21/1000 patient-years in the last decade[[23](#_ENREF_23)]. The risk of CRC of longstanding Crohn's colitis is considered to be similar to that of UC, while the incidence of CRC in Crohn's disease showed various ranges in cancer risk[[24-27](#_ENREF_24)].

Patients with UC who have undergone proctocolectomy have a very small risk of dysplasia in the ileal pouch[[28](#_ENREF_28)]. Anal transitional zone dysplasia after ileal pouch-anal anastomosis is infrequent. Anal transitional zone preservation did not lead to the development of cancer in the anal transitional zone after five to ten years of follow-up[[29](#_ENREF_29)].

The prognosis of CRC is poorer for UC patients than for patients without UC[[30-33](#_ENREF_30)], and the long term prognosis of UC-CRC is even worse, when patients with the same tumor stage are compared[[32](#_ENREF_32)]. UC-CRC has been frequently found at advanced stage[[33](#_ENREF_33)]. These findings suggest the importance of knowledge of risk factor for UC-CRC and surveillance for patients with UC.

**RISK FACTORS OF UC-CRC**

Knowledge of risk factor for CRC is important to categorize subgroups of UC patients who need frequent surveillance or intense treatment. Risk factors for CRC in UC patients include, anatomic extent, young age at diagnosis, and duration of disease, concurrent primary sclerosing cholangitis (PSC), and family history of CRC. In addition, smoking, pseudopolyps, persisting inflammation of the colon and backwash ileitis are also risk factor for CRC[[34](#_ENREF_34),[35](#_ENREF_35)]. These UC patients with risk factors should be enrolled in intensive surveillance program.

***Pancolitis***

Anatomic extent of colitis is an independent risk factor for the development of CRC. A meta-analysis showed that the incidence of CRC in patients with extensive UC was 5.4%[[36](#_ENREF_36)]. Patients with pancolitis are at high risk of CRC, left-sided colitis are moderate, and proctitis and protosigmoiditis are low as similar as the non-UC population[[20](#_ENREF_20),[37](#_ENREF_37),[38](#_ENREF_38)]. Ekbom *et al*[[38](#_ENREF_38)] reported that UC patients with pancolitis had a 15-fold higher risk of CRC as compared to the non-UC group, in contrast to an increased risk of 2.8 for patients with left-sided colitis and no significant increased risk for those with proctitis, and reported an overall risk of 4.8 for UC patients with extensive disease.

***Young age***

Young age at onset of colitis has been reported to be an independent risk factor for CRC[[6](#_ENREF_6)]. CRC risk varied by age at initial diagnosis of UC; patients diagnosed at childhood (0-19 years old) had the risk with a relative risk of 43.8 followed by those diagnosed in young (20-39 years old) with a relative risk of 2.65[[39](#_ENREF_39)].

***Long disease duration***

Duration of UC is one of important risk factors for CRC development. Patients with IBD for whom the median time from diagnosis of IBD to CRC was 17 years, 21% of the tumors developed within 10 years after onset[[40](#_ENREF_40)].

***PSC***

IBD patients with PSC, a chronic cholestatic liver disease, had an increased risk of CRC[[41](#_ENREF_41)]. Broome *et al*[[42](#_ENREF_42)] revealed a cumulative risk of CRC in UC patients with PSC of 9% after 10 years duration of symptom, 31% after 20 years and as high as 50% after 25 years; compared with 2%, 5% and 10% in patients with UC alone matched for each duration. A meta-analysis found that 21% of UC patients with PSC developed CRC in compared to 4% of UC patients without PSC. The risk of CRC in UC patients with PSC was 4.8-fold higher than that in patients with UC without PSC[[43](#_ENREF_43)].

***Family history of colorectal cancer***

A family history of CRC in UC patients increases the risk of CRC, irrespectively of type and extent of IBD, as compared to patients with UC without positive family history for CRC[[44-46](#_ENREF_44)].

**MOLECULAR FEATURES OF UC-CRC**

Genetic characteristics detected in sporadic CRC such as genetic mutations, microsatellite instability (MSI), and DNA hypermethylation were also recognized in UC-CRC[[4](#_ENREF_4),[33](#_ENREF_33),[47-50](#_ENREF_47)]. *p53* mutations occur early in the adenoma-carcinoma sequence and are often detected in non-dysplastic or indefinite dysplasia in UC, while *p53* mutations occur late phase in the sporadic adenoma[[51](#_ENREF_51)]. MSI is also relatively frequent in non-dysplastic inflamed epithelia, and transforming growth factor β receptor type II (*TGFβRII)* mutation is one of target genes by MSI process in UC-CRC[[50](#_ENREF_50)]. Hyper-methylation in hMLH1[[50](#_ENREF_50),[52](#_ENREF_52)], p16INK4a[[53](#_ENREF_53)], and p14ARF[[54](#_ENREF_54)] seems to precede dysplasia and contribute to the genetic alterations in UC-CRC[[55](#_ENREF_55)]. MicroRNAs play a critical role in regulating key pathogenic mechanism in IBD[[56](#_ENREF_56)]. MicroRNA-124a gene, showing tumor-suppressive function, are methylated during carcinogenesis in UC patients, and the methylation level of miR-124a-3 is a promising marker for estimating individual risk for CAC[[57](#_ENREF_57)]. In contrast, MicroRNA-155 overexpression being particularly associated to MSI in CA-CRC[[58](#_ENREF_58)]. These molecules might be useful biomarkers for early detection and treatment response of CRC in IBD patients.

The inflammatory stresses, such as reactive oxygen species and some free radicals, may cause these genetic damages[[59](#_ENREF_59)-61] and are considered to be factors for the pathogenesis of UC-CRC[[62](#_ENREF_62),63].

**SURVEILLANCE COLONOSCOPY**

Cancer surveillance is based on the high-risk factors that identify patients who are likely to develop cancer. The management of UC has changed with biological therapies, surgical treatment, and surveillance tools, which reduced the risk of CRC in patients with UC[[9](#_ENREF_9),[20](#_ENREF_20),[23](#_ENREF_23)]. Surveillance is recommended to be performed during remission state in order to reduce the difficulty of differentiating reactive change from dysplasia[[64](#_ENREF_64)].Data from the 18-year surveillance program demonstrated that cancer was detected at an early stage in 80% of surveyed patients, compared with only 41% of non-surveyed UC patients[[65](#_ENREF_65)]. There is evidence that surveillance colonoscopy reduces the risk of CRC and mortality in UC: the overall 5-year survival rate was 77% for the surveillance group, compared with only 36% for the control group[[33](#_ENREF_33),[35](#_ENREF_35),[65](#_ENREF_65)]. It has been reported that a prior history of surveillance colonoscopy reduces the odds of developing CRC by 60%-80%[[35](#_ENREF_35),[66](#_ENREF_66)].

These guidelines, commissioned by the Clinical Services’ Committee of the British Society of Gastroenterology for clinicians and allied professionals caring for patients with IBD in the United Kingdom, provide an good clinical practice for surveillance and treatment[[67](#_ENREF_67)]. The guidelines state that UC patients should be advised to have a review colonoscopy 8-10 years after disease onset to check the extent of colitis. Current recommendations are for regular surveillance every 1-2 years in the second decade of disease to yearly by the fourth decade. The recommended guidelines for the surveillance of CRC in UC by some societies[[67-75](#_ENREF_67)], and are summarized in the Table 2. These recommend surveillance programs are synthetized as follows: (1) Surveillance colonoscopy should be performed during remission state; (2) Initial surveillance colonoscopy for CRC should be performed 8–10 years after onset; (3) Regular surveillance should be performed annually or biannually; (4) Surveillance colonoscopy for patients with PSC should be performed annually from the beginning of PSC diagnosis; (5) Random biopsy of four lesions might be taken every 10 cm through the colon; and (6) If dysplasia is detected, the biopsies should be reviewed by a second gastrointestinal pathologist.

The main aim of surveillance programs is to detect dysplastic alterations. The cumulative probability of developing dysplasia or CRC in UC patients was 7.7% at 20 years and 15.8% at 30 years[[13](#_ENREF_13)]. CRC incidence was 14 of 1000 UC patients-years' duration and the incidence of any advanced lesion was 30 of 1000 person-years' duration. When low-grade dysplasia (LGD) is detected on surveillance there is a 9-fold risk of developing cancer and 12-fold risk of developing any advanced lesion[[76](#_ENREF_76)]. Among patients with LGD who undergo colectomy, 19% will already harbor CRC or high-grade dysplasia (HGD) and 30%-50% will develop advanced neoplasia over the following 5 years[[77-79](#_ENREF_77)]. HGD carries a 43% risk of synchronous cancer[[80](#_ENREF_80)].

The guidelines described random biopsy[[67](#_ENREF_67)]. A study of multiple biopsies taken at colonoscopy suggested that 33 biopsies are required to give a 95% chance of detecting dysplasia[[81](#_ENREF_81)]. In contrast, targeted biopsies are recommended to increase the frequency of dysplasia detection, in compared with random biopsies. Chromoendoscopy might improve the imagining of subtle mucosal changes those are suspicious of neoplasia, in compared with standard endoscopy[[82](#_ENREF_82)]. Indigo carmine contrast dye highlights irregularities in the mucosal architecture, improving the precision of endoscopic diagnosis. Methylene blue stains normal epithelium of the colon; the absence of staining might indicate the presence of neoplastic change of intestine. Magnifying endoscopy could assist us to further visualize the delicate surface patterns[[83](#_ENREF_83)].

On the other hand, some studies have highlighted the failures of surveillance colonoscopy by the guidelines[[39](#_ENREF_39),[84](#_ENREF_84),[85](#_ENREF_85)]. In 50%-80% of cases with colitis-associated neoplasms, the lesions are not visible upon endoscopy[[38](#_ENREF_38)]. It would be necessary to clarify that the surveillance systems could contribute to the decline of the mortality of UC patients.

**TREATMENT FOR DYSPLASIA**

Histopathological diagnosis of polypoid mucosa of UC is important with respect to clinical treatment for dysplasia. UC with HGD usually lead to a total colectomy because of the high incidence of adenocarcinoma (42%–67% of the colectomy specimens)[75,[79](#_ENREF_79),[86](#_ENREF_87)].. When HGD in flat mucosa was the initial discovery, surgery or polypectomy is done. Polypectomy should be performed along with biopsies taken from the surrounding mucosa. If the polypectomy is confirmed to be complete and biopsies of the adjacent mucosa are negative for dysplasia, a follow-up examination within 6 months should be performed[[75](#_ENREF_75),[78](#_ENREF_78)]. If the dysplastic lesion remains to be persistent or “dysplasia associated lesions or masses” (DALM) exists, a proctocolectomy should be performed[[75](#_ENREF_75)].

In contrast, the management of LGD is controversial[[87](#_ENREF_88)]. About 30%-50% of patients with LGD progressed to HGD or CRC, an unrecognized synchronous CRC may already be present in up to 20% of UC patients with LGD[[77](#_ENREF_77),[79](#_ENREF_79)], which indicated that LGD is a risk factor for CRC.In contrast, some studies have shown that patients with LGD have a lower rate of CRC than previously reported[[88](#_ENREF_89)].

Dysplasia found in DALM or in areas without any macroscopically visible mucosal alteration is believed to be the origin CRC[[89](#_ENREF_90),[90](#_ENREF_91)]. The guidelines also state that particular attention should be paid to DALM which harbor a high risk of progression to CRC[[71](#_ENREF_71)]. And patients with DALM are recommended to undergo prophylactic proctocolectomy with ileoanal pouch. In contrast, some polyps such as adenoma-like mass (ALM) that is unrelated to colitis and can be managed by endoscopic polypectomybecause of less carcinogenic potential[[91](#_ENREF_92)].

The serrated neoplasia pathway was recently proposed in CRC[[92](#_ENREF_93)]. Serrated epithelial changes and sessile serrated polyps are uncommonly detected (0.2%-1%) by colonoscopy in chronic ulcerative colitis and Crohn's disease patients[[93](#_ENREF_94)], while Bossard *et al*[[94](#_ENREF_95)] found that serrated lesions, such as hyperplastic polyps and sessile serrated polyps/adenomas, accounted for approximately 7% of premalignant lesions in the inflamed mucosa in patients with IBD.

**CHEMOPREVENTION**

Chemoprevention refers to the use of a medication of anti-inflammatory therapy or other substance to reduce or prevent the development of cancer. The current decreased incidence of CAC might be due to a better control of inflammation by improved medical therapy and higher rates of mucosal healing[[95](#_ENREF_96)]. Intervening before the development of neoplasia might be promising to decrease cancer and prevent colectomy.

***5-ASA***

5-ASA, the nuclear kappa-B pathway inhibitor, is the first line agent for anti-inflammatory therapy[[96](#_ENREF_97)]. Since continuing inflammation is a plausible mechanism causing malignant transformation, anti-inflammatory therapy might be useful for chemopreventionin UC patients. 5-ASA reduces oxidative stress, inhibits cell proliferation, and promotes apoptosis[[96](#_ENREF_97)]. Most reports indicated that 5-ASA reduces the risk of CRC in chronic ulcerative colitis[[34](#_ENREF_34),[35](#_ENREF_35),97,98] but some reports against. A meta-analysis performed by Velayos *et al*[85] showed a protective association between use of 5-ASA and CRC or a combined end point of CRC/dysplasia: in a pooled analysis of 334 CRC cases among patients with UC, regular use of 5-ASA reduced the risk of CRC by approximately 50%, similar to the regular use of NSAIDs in patients without UC[[99](#_ENREF_100)]. In contrast, several studies did not find any chemopreventive effect of 5-ASA[[100-102](#_ENREF_101)].

***Ursodeoxycholic acid***

Ursodeoxycholic acid (UDCA) may be a practical chemoprevention against colonic exposure to bile acid in patients with PSC[[103](#_ENREF_104)]. UDCA use was closely associated with decreased prevalence of neoplasia because UDCA reduces the colonic concentration of the secondary bile acid as a carcinogen[[104](#_ENREF_105),[105](#_ENREF_106)]. It has been reported that UDCA reduced the risk of CRC in PSC patients with IBD by 80%[[103](#_ENREF_104)].

***Steroids, aspirin, NSAIDs***

There are several studies that suggest steroids, aspirin, and NSAIDs may reduce the incidence and mortality of CRC in UC[[34](#_ENREF_34),[35](#_ENREF_35),[106](#_ENREF_107)].

***Total colectomy***

The cumulative CRC risk in patients with UC is 30%-40% at 20-30 years after onset of disease, which might suggest that total colectomy is recommend after 15 years of disease in patients with UC. However the role for prophylactic colectomy in patients with IBD remains to be controversial.

**FUTURE DIRECTION**

Accumulation of studies about UC-CRC leads us a common-sense that control of long-term background inflammation and mucosal damage. The use of maintenance chronic ulcerative colitis therapies could be a potentially important strategy for reducing CRC risk in UC patients. Inflammatory stresses, such as reactive oxygen species and some free radicals, have been considered to cause genetic damages of UC epithelium. UC-CRC shows characteristic clinicopathological features. Analysis of the correlation between these genetic features and clinicopathologic features might be useful to develop a new therapy and to reduce a risk for UC-CRC in future.

**References**

1 **Dobbins WO**. Dysplasia and malignancy in inflammatory bowel disease. *Annu Rev Med* 1984; **35**: 33-48 [PMID: 6372661 DOI: 10.1146/annurev.me.35.020184.000341]

2 **Isbell G**, Levin B. Ulcerative colitis and colon cancer. *Gastroenterol Clin North Am* 1988; **17**: 773-791 [PMID: 3068141]

3 **Chambers WM**, Warren BF, Jewell DP, Mortensen NJ. Cancer surveillance in ulcerative colitis. *Br J Surg* 2005; **92**: 928-936 [PMID: 16034807]

4 **Grivennikov SI**. Inflammation and colorectal cancer: colitis-associated neoplasia. *Semin Immunopathol* 2013; **35**: 229-244 [PMID: 23161445 DOI: 10.1007/s00281-012-0352-6]

5 **Gyde S**, Prior P, Dew MJ, Saunders V, Waterhouse JA, Allan RN. Mortality in ulcerative colitis. *Gastroenterology* 1982; **83**: 36-43 [PMID: 7075944]

6 **Ekbom A**, Adami HO, Helmick CG, Jonzon A, Zack MM. Perinatal risk factors for inflammatory bowel disease: a case-control study. *Am J Epidemiol* 1990; **132**: 1111-1119 [PMID: 2260543]

7 **Langholz E**, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. *Gastroenterology* 1992; **103**: 1444-1451 [PMID: 1358741]

8 **Bernstein CN**, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. *Cancer* 2001; **91**: 854-862 [PMID: 11241255 DOI: 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z]

9 **Eaden JA**, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001; **48**: 526-535 [PMID: 11247898 DOI: 10.1136/gut.48.4.526]

10 **Karlén P**, Löfberg R, Broström O, Leijonmarck CE, Hellers G, Persson PG. Increased risk of cancer in ulcerative colitis: a population-based cohort study. *Am J Gastroenterol* 1999; **94**: 1047-1052 [PMID: 10201481 DOI: 10.1111/j.1572-0241.1999.01012.x]

11 **Gyde SN**, Prior P, Allan RN, Stevens A, Jewell DP, Truelove SC, Lofberg R, Brostrom O, Hellers G. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. *Gut* 1988; **29**: 206-217 [PMID: 3345932 DOI: 10.1136/gut.29.2.206]

12 **Broström O**, Löfberg R, Nordenvall B, Ost A, Hellers G. The risk of colorectal cancer in ulcerative colitis. An epidemiologic study. *Scand J Gastroenterol* 1987; **22**: 1193-1199 [PMID: 3433007 DOI: 10.3109/00365528708996463]

13 **Lennard-Jones JE**, Melville DM, Morson BC, Ritchie JK, Williams CB. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. *Gut* 1990; **31**: 800-806 [PMID: 2370015 DOI: 10.1136/gut.31.7.800]

14 **Gilat T**, Fireman Z, Grossman A, Hacohen D, Kadish U, Ron E, Rozen P, Lilos P. Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. *Gastroenterology* 1988; **94**: 870-877 [PMID: 3345886]

15 **Collins RH**, Feldman M, Fordtran JS. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review. *N Engl J Med* 1987; **316**: 1654-1658 [PMID: 3295551 DOI: 10.1056/NEJM198706253162609]

16 **Löfberg R**, Broström O, Karlén P, Tribukait B, Ost A. Colonoscopic surveillance in long-standing total ulcerative colitis--a 15-year follow-up study. *Gastroenterology* 1990; **99**: 1021-1031 [PMID: 2394325]

17 **Lakatos L**, Mester G, Erdelyi Z, David G, Pandur T, Balogh M, Fischer S, Vargha P, Lakatos PL. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. *Inflamm Bowel Dis* 2006; **12**: 205-211 [PMID: 16534422 DOI: 10.1097/01.MIB.0000217770.21261.ce]

18 **Winther KV**, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. *Clin Gastroenterol Hepatol* 2004; **2**: 1088-1095 [PMID: 15625654 DOI: 10.1016/S1542-3565(04)00543-9]

19 **Rutter MD**, Saunders BP, Wilkinson KH, Schofield G, Forbes A. Intangible costs and benefits of ulcerative colitis surveillance: a patient survey. *Dis Colon Rectum* 2006; **49**: 1177-1183 [PMID: 16763757 DOI: 10.1007/s10350-006-0546-x]

20 **Söderlund S**, Brandt L, Lapidus A, Karlén P, Broström O, Löfberg R, Ekbom A, Askling J. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. *Gastroenterology* 2009; **136**: 1561-157; quiz 1561-157; [PMID: 19422077]

21 **Manninen P**, Karvonen AL, Huhtala H, Aitola P, Hyöty M, Nieminen I, Hemminki H, Collin P. The risk of colorectal cancer in patients with inflammatory bowel diseases in Finland: a follow-up of 20 years. *J Crohns Colitis* 2013; **7**: e551-e557 [PMID: 23619008 DOI: 10.1016/j.crohns.2013.04.003]

22 **Hata K**, Watanabe T, Kazama S, Suzuki K, Shinozaki M, Yokoyama T, Matsuda K, Muto T, Nagawa H. Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population. *Br J Cancer* 2003; **89**: 1232-1236 [PMID: 14520452 DOI: 10.1038/sj.bjc.6601247]

23 **Castaño-Milla C**, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. *Aliment Pharmacol Ther* 2014; **39**: 645-659 [PMID: 24612141 DOI: 10.1111/apt.12651]

24 **Mellemkjaer L**, Johansen C, Gridley G, Linet MS, Kjaer SK, Olsen JH. Crohn's disease and cancer risk (Denmark). *Cancer Causes Control* 2000; **11**: 145-150 [PMID: 10710198 DOI: 10.1023/A: 1008988215904]

25 **Ekbom A**, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. *Lancet* 1990; **336**: 357-359 [PMID: 1975343 DOI: 10.1016/0140-6736(90)91889-I]

26 **Persson PG**, Karlén P, Bernell O, Leijonmarck CE, Broström O, Ahlbom A, Hellers G. Crohn's disease and cancer: a population-based cohort study. *Gastroenterology* 1994; **107**: 1675-1679 [PMID: 7958678]

27 **Sachar DB**. Cancer in Crohn's disease: dispelling the myths. *Gut* 1994; **35**: 1507-1508 [PMID: 7828962 DOI: 10.1136/gut.35.11.1507]

28 **Herline AJ**, Meisinger LL, Rusin LC, Roberts PL, Murray JJ, Coller JA, Marcello PW, Schoetz DJ. Is routine pouch surveillance for dysplasia indicated for ileoanal pouches? *Dis Colon Rectum* 2003; **46**: 156-159 [PMID: 12576887 DOI: 10.1097/01.DCR.0000049346.48395.4D]

29 **O'Riordain MG**, Fazio VW, Lavery IC, Remzi F, Fabbri N, Meneu J, Goldblum J, Petras RE. Incidence and natural history of dysplasia of the anal transitional zone after ileal pouch-anal anastomosis: results of a five-year to ten-year follow-up. *Dis Colon Rectum* 2000; **43**: 1660-1665 [PMID: 11156448 DOI: 10.1007/BF02236846]

30 **Averboukh F**, Ziv Y, Kariv Y, Zmora O, Dotan I, Klausner JM, Rabau M, Tulchinsky H. Colorectal carcinoma in inflammatory bowel disease: a comparison between Crohn's and ulcerative colitis. *Colorectal Dis* 2011; **13**: 1230-1235 [PMID: 21689324 DOI: 10.1111/j.1463-1318.2011.02639.x]

31 **Sugita A**, Greenstein AJ, Ribeiro MB, Sachar DB, Bodian C, Panday AK, Szporn A, Pozner J, Heimann T, Palmer M. Survival with colorectal cancer in ulcerative colitis. A study of 102 cases. *Ann Surg* 1993; **218**: 189-195 [PMID: 8342999]

32 **Watanabe T**, Konishi T, Kishimoto J, Kotake K, Muto T, Sugihara K. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. *Inflamm Bowel Dis* 2011; **17**: 802-808 [PMID: 20848547 DOI: 10.1002/ibd.21365]

33 **Kavanagh DO**, Carter MC, Keegan D, Doherty G, Smith MJ, Hyland JM, Mulcahy H, Sheahan K, O' Connell PR, O' Donoghue DP, Winter DC. Management of colorectal cancer in patients with inflammatory bowel disease. *Tech Coloproctol* 2014; **18**: 23-28 [PMID: 23407916 DOI: 10.1007/s10151-013-0981-3]

34 **Pinczowski D**, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. *Gastroenterology* 1994; **107**: 117-120 [PMID: 7912678]

35 **Velayos FS**, Loftus EV, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. *Gastroenterology* 2006; **130**: 1941-1949 [PMID: 16762617 DOI: 10.1053/j.gastro.2006.03.028]

36 **Xie J**, Itzkowitz SH. Cancer in inflammatory bowel disease. *World J Gastroenterol* 2008; **14**: 378-389 [PMID: 18200660 DOI: 10.3748/wjg.14.378]

37 **Jess T**, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. *Clin Gastroenterol Hepatol* 2012; **10**: 639-645 [PMID: 22289873 DOI: 10.1016/j.cgh.2012.01.010]

38 **Ekbom A**, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. *N Engl J Med* 1990; **323**: 1228-1233 [PMID: 2215606 DOI: 10.1056/NEJM199011013231802]

39 **Jess T**, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. *Gastroenterology* 2012; **143**: 375-81.e1; quiz e13-4 [PMID: 22522090 DOI: 10.1053/j.gastro.2012.04.016]

40 **Brackmann S**, Andersen SN, Aamodt G, Langmark F, Clausen OP, Aadland E, Fausa O, Rydning A, Vatn MH. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. *Scand J Gastroenterol* 2009; **44**: 46-55 [PMID: 18609187 DOI: 10.1080/00365520801977568]

41 **Molodecky NA**, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, Kaplan GG. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. *Hepatology* 2011; **53**: 1590-1599 [PMID: 21351115 DOI: 10.1002/hep.24247]

42 **Broomé U**, Löfberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. *Hepatology* 1995; **22**: 1404-1408 [PMID: 7590655]

43 **Soetikno RM**, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. *Gastrointest Endosc* 2002; **56**: 48-54 [PMID: 12085034 DOI: 10.1067/mge.2002.125367]

44 **Askling J**, Dickman PW, Karlén P, Broström O, Lapidus A, Löfberg R, Ekbom A. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. *Gastroenterology* 2001; **120**: 1356-1362 [PMID: 11313305 DOI: 10.1053/gast.2001.24052]

45 **Nuako KW**, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. *Gastroenterology* 1998; **115**: 1079-1083 [PMID: 9797361 DOI: 10.1016/S0016-5085(98)70077-0]

46 **Askling J**, Dickman PW, Karlén P, Broström O, Lapidus A, Löfberg R, Ekbom A. Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. *Lancet* 2001; **357**: 262-266 [PMID: 11214128 DOI: 10.1016/S0140-6736(00)03612-6]

47 **Willenbucher RF**, Aust DE, Chang CG, Zelman SJ, Ferrell LD, Moore DH, Waldman FM. Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. *Am J Pathol* 1999; **154**: 1825-1830 [PMID: 10362807 DOI: 10.1016/S0002-9440(10)65438-7]

48 **Cottliar A**, Fundia A, Boerr L, Sambuelli A, Negreira S, Gil A, Gómez JC, Chopita N, Bernedo A, Slavutsky I. High frequencies of telomeric associations, chromosome aberrations, and sister chromatid exchanges in ulcerative colitis. *Am J Gastroenterol* 2000; **95**: 2301-2307 [PMID: 11007232 DOI: 10.1111/j.1572-0241.2000.02315.x]

49 **Løvig T**, Andersen SN, Clausen OP, Rognum TO. Microsatellite instability in long-standing ulcerative colitis. *Scand J Gastroenterol* 2007; **42**: 586-591 [PMID: 17454879 DOI: 10.1080/00365520601013747]

50 **Fujiwara I**, Yashiro M, Kubo N, Maeda K, Hirakawa K. Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway. *Dis Colon Rectum* 2008; **51**: 1387-1394 [PMID: 18546042 DOI: 10.1007/s10350-008-9212-9]

51 **Shigaki K**, Mitomi H, Fujimori T, Ichikawa K, Tomita S, Imura J, Fujii S, Itabashi M, Kameoka S, Sahara R, Takenoshita S. Immunohistochemical analysis of chromogranin A and p53 expressions in ulcerative colitis-associated neoplasia: neuroendocrine differentiation as an early event in the colitis-neoplasia sequence. *Hum Pathol* 2013; **44**: 2393-2399 [PMID: 24029705 DOI: 10.1016/j.humpath.2013.06.008]

52 **Fleisher AS**, Esteller M, Harpaz N, Leytin A, Rashid A, Xu Y, Liang J, Stine OC, Yin J, Zou TT, Abraham JM, Kong D, Wilson KT, James SP, Herman JG, Meltzer SJ. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. *Cancer Res* 2000; **60**: 4864-4868 [PMID: 10987299]

53 **Hsieh CJ**, Klump B, Holzmann K, Borchard F, Gregor M, Porschen R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. *Cancer Res* 1998; **58**: 3942-3945 [PMID: 9731506]

54 **Moriyama T**, Matsumoto T, Nakamura S, Jo Y, Mibu R, Yao T, Iida M. Hypermethylation of p14 (ARF) may be predictive of colitic cancer in patients with ulcerative colitis. *Dis Colon Rectum* 2007; **50**: 1384-1392 [PMID: 17665255 DOI: 10.1007/10350-007-0302-x]

55 **Maeda O**, Ando T, Watanabe O, Ishiguro K, Ohmiya N, Niwa Y, Goto H. DNA hypermethylation in colorectal neoplasms and inflammatory bowel disease: a mini review. *Inflammopharmacology* 2006; **14**: 204-206 [PMID: 17093903 DOI: 10.1007/s10787-006-1540-6]

56 **Chen WX**, Ren LH, Shi RH. Implication of miRNAs for inflammatory bowel disease treatment: Systematic review. *World J Gastrointest Pathophysiol* 2014; **5**: 63-70 [PMID: 24891977 DOI: 10.4291/wjgp.v5.i2.63]

57 **Ueda Y**, Ando T, Nanjo S, Ushijima T, Sugiyama T. DNA Methylation of MicroRNA-124a Is a Potential Risk Marker of Colitis-Associated Cancer in Patients with Ulcerative Colitis. *Dig Dis Sci* 2014; **59**: 2444-2451 [PMID: 24825593 DOI: 10.1007/s10620-014-3193-4]

58 **Svrcek M**, El-Murr N, Wanherdrick K, Dumont S, Beaugerie L, Cosnes J, Colombel JF, Tiret E, Fléjou JF, Lesuffleur T, Duval A. Overexpression of microRNAs-155 and 21 targeting mismatch repair proteins in inflammatory bowel diseases. *Carcinogenesis* 2013; **34**: 828-834 [PMID: 23288924 DOI: 10.1093/carcin/bgs408]

59 **Thorsteinsdottir S**, Gudjonsson T, Nielsen OH, Vainer B, Seidelin JB. Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. *Nat Rev Gastroenterol Hepatol* 2011; **8**: 395-404 [PMID: 21647200 DOI: 10.1038/nrgastro.2011.96]

60 **Hussain SP**, Hofseth LJ, Harris CC. Radical causes of cancer. *Nat Rev Cancer* 2003; **3**: 276-285 [PMID: 12671666 DOI: 10.1038/nrc1046]

61 **Marnett LJ**. Oxyradicals and DNA damage. *Carcinogenesis* 2000; **21**: 361-370 [PMID: 10688856 DOI: 10.1093/carcin/21.3.361]

62 **McKenzie SJ**, Baker MS, Buffinton GD, Doe WF. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. *J Clin Invest* 1996; **98**: 136-141 [PMID: 8690784 DOI: 10.1172/JCI118757]

63 **D'Incà R**, Cardin R, Benazzato L, Angriman I, Martines D, Sturniolo GC. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. *Inflamm Bowel Dis* 2004; **10**: 23-27 [PMID: 15058522 DOI: 10.1097/00054725-200401000-00003]

64 **Riddell RH**, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. *Hum Pathol* 1983; **14**: 931-968 [PMID: 6629368]

65 **Choi PM**, Nugent FW, Schoetz DJ, Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. *Gastroenterology* 1993; **105**: 418-424 [PMID: 8335197]

66 **Karlén P**, Kornfeld D, Broström O, Löfberg R, Persson PG, Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. *Gut* 1998; **42**: 711-714 [PMID: 9659169 DOI: 10.1136/gut.42.5.711]

67 **Carter MJ**, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. *Gut* 2004; **53** Suppl 5: V1-16 [PMID: 15306569 DOI: 10.1136/gut.2004.043372]

68 **Cairns SR**, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, Woodhouse CR. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). *Gut* 2010; **59**: 666-689 [PMID: 20427401 DOI: 10.1136/gut.2009.179804]

69 **Leighton JA**, Shen B, Baron TH, Adler DG, Davila R, Egan JV, Faigel DO, Gan SI, Hirota WK, Lichtenstein D, Qureshi WA, Rajan E, Zuckerman MJ, VanGuilder T, Fanelli RD. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. *Gastrointest Endosc* 2006; **63**: 558-565 [PMID: 16564852 DOI: 10.1016/j.gie.2006.02.005]

70 **Kornbluth A**, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol* 2010; **105**: 501-23; quiz 524 [PMID: 20068560 DOI: 10.1038/ajg.2009.727]

71 **Eaden JA**, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. *Gut* 2002; **51** Suppl 5: V10-V12 [PMID: 12221032 DOI: 10.1136/gut.51.suppl\_5.v10]

72 **Farraye FA**, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. *Gastroenterology* 2010; **138**: 746-74, 774.e1-4; quiz e12-3 [PMID: 20141809 DOI: 10.1053/j.gastro.2009.12.035]

73 **Van Assche G**, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. *J Crohns Colitis* 2013; **7**: 1-33 [PMID: 23040453 DOI: 10.1016/j.crohns.2012.09.005]

74 **Biancone L**, Michetti P, Travis S, Escher JC, Moser G, Forbes A, Hoffmann JC, Dignass A, Gionchetti P, Jantschek G, Kiesslich R, Kolacek S, Mitchell R, Panes J, Soderholm J, Vucelic B, Stange E. European evidence-based Consensus on the management of ulcerative colitis: Special situations. *J Crohns Colitis* 2008; **2**: 63-92 [PMID: 21172196 DOI: 10.1016/j.crohns.2007.12.001]

75 **Itzkowitz SH**, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. *Inflamm Bowel Dis* 2005; **11**: 314-321 [PMID: 15735438 DOI: 10.1097/01.MIB.0000160811.76729.d5]

76 **Thomas T**, Abrams KA, Robinson RJ, Mayberry JF. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. *Aliment Pharmacol Ther* 2007; **25**: 657-668 [PMID: 17311598 DOI: 10.1111/j.1365-2036.2007.03241.x]

77 **Ullman T**, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. *Gastroenterology* 2003; **125**: 1311-1319 [PMID: 14598247 DOI: 10.1016/j.gastro.2003.08.023]

78 **Odze RD**, Farraye FA, Hecht JL, Hornick JL; Crohn's and Colitis Foundation of America Colon Cancer in IBD Study Group. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. *Clin Gastroenterol Hepatol* 2004; **2**: 534-541 [PMID: 15224277 DOI: 10.1016/S1542-3565(04)00237-X]

79 **Bernstein CN**, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? *Lancet* 1994; **343**: 71-74 [PMID: 7903776 DOI: 10.1016/S0140-6736(94)90813-3]

80 **Kornfeld D**, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. *Gut* 1997; **41**: 522-525 [PMID: 9391253 DOI: 10.1136/gut.41.4.522]

81 **Rubin CE**, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, Rabinovitch PS. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. *Gastroenterology* 1992; **103**: 1611-1620 [PMID: 1426881]

82 **Mitooka H**, Fujimori T, Ohno S, Morimoto S, Nakashima T, Ohmoto A, Okano H, Miyamoto M, Oh T, Saeki S. Chromoscopy of the colon using indigo carmine dye with electrolyte lavage solution. *Gastrointest Endosc* 1992; **38**: 373-374 [PMID: 1607092 DOI: 10.1016/S0016-5107(92)70436-2]

83 **Oka S**, Tanaka S, Chayama K. Detection of nonpolypoid colorectal neoplasia using magnifying endoscopy in colonic inflammatory bowel disease. *Gastrointest Endosc Clin N Am* 2014; **24**: 405-417 [PMID: 24975531 DOI: 10.1016/j.giec.2014.03.011]

84 **Jess T**, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. *Clin Gastroenterol Hepatol* 2013; **11**: 43-48 [PMID: 23022699 DOI: 10.1016/j.cgh.2012.09.026]

85 **Herrinton LJ**, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. *Gastroenterology* 2012; **143**: 382-389 [PMID: 22609382 DOI: 10.1053/j.gastro.2012.04.054]

86 **Kornbluth A**, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol* 2004; **99**: 1371-1385 [PMID: 15233681 DOI: 10.1111/j.1572-0241.2004.40036.x]

87 **Pekow JR**, Hetzel JT, Rothe JA, Hanauer SB, Turner JR, Hart J, Noffsinger A, Huo D, Rubin DT. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. *Inflamm Bowel Dis* 2010; **16**: 1352-1356 [PMID: 20027656 DOI: 10.1002/ibd.21184]

88 **Befrits R**, Ljung T, Jaramillo E, Rubio C. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. *Dis Colon Rectum* 2002; **45**: 615-620 [PMID: 12004210 DOI: 10.1007/s10350-004-6255-4]

89 **Kiran RP**, Ali UA, Nisar PJ, Khoury W, Gu J, Shen B, Remzi FH, Hammel JP, Lavery IC, Fazio VW, Goldblum JR. Risk and location of cancer in patients with preoperative colitis-associated dysplasia undergoing proctocolectomy. *Ann Surg* 2014; **259**: 302-309 [PMID: 23579580 DOI: 10.1097/SLA.0b013e31828e7417]

90 **Chen YX**, Qiao L. Adenoma-like and non-adenoma-like dysplasia-associated lesion or mass in ulcerative colitis. *J Dig Dis* 2013; **14**: 157-159 [PMID: 23374421 DOI: 10.1111/1751-2980.12043]

91 **Torres C**, Antonioli D, Odze RD. Polypoid dysplasia and adenomas in inflammatory bowel disease: a clinical, pathologic, and follow-up study of 89 polyps from 59 patients. *Am J Surg Pathol* 1998; **22**: 275-284 [PMID: 9500769 DOI: 10.1097/00000478-199803000-00001]

92 **Yashiro M**, Laghi L, Saito K, Carethers JM, Slezak P, Rubio C, Hirakawa K, Boland CR. Serrated adenomas have a pattern of genetic alterations that distinguishes them from other colorectal polyps. *Cancer Epidemiol Biomarkers Prev* 2005; **14**: 2253-2256 [PMID: 16172239 DOI: 10.1158/1055-9965.EPI-04-0790]

93 **Johnson DH**, Khanna S, Smyrk TC, Loftus EV, Anderson KS, Mahoney DW, Ahlquist DA, Kisiel JB. Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitis. *Aliment Pharmacol Ther* 2014; **39**: 1408-1417 [PMID: 24779703 DOI: 10.1111/apt.12774]

94 **Bossard C**, Denis MG, Bézieau S, Bach-Ngohou K, Bourreille A, Laboisse CL, Mosnier JF. Involvement of the serrated neoplasia pathway in inflammatory bowel disease-related colorectal oncogenesis. *Oncol Rep* 2007; **18**: 1093-1097 [PMID: 17914558]

95 **Rogler G**. Chronic ulcerative colitis and colorectal cancer. *Cancer Lett* 2014; **345**: 235-241 [PMID: 23941831 DOI: 10.1016/j.canlet.2013.07.032]

96 **Kaiser GC**, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. *Gastroenterology* 1999; **116**: 602-609 [PMID: 10029619 DOI: 10.1016/S0016-5085(99)70182-4]

97 **van Staa TP**, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. *Gut* 2005; **54**: 1573-1578 [PMID: 15994215 DOI: 10.1136/gut.2005.070896]

98 **Eaden J**, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. *Aliment Pharmacol Ther* 2000; **14**: 145-153 [PMID: 10651654 DOI: 10.1046/j.1365-2036.2000.00698.x]

99 **Velayos FS**, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. *Am J Gastroenterol* 2005; **100**: 1345-1353 [PMID: 15929768 DOI: 10.1111/j.1572-0241.2005.41442.x]

100 **Bernstein CN**, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. *Am J Gastroenterol* 2011; **106**: 731-736 [PMID: 21407180 DOI: 10.1038/ajg.2011.50]

101 **Terdiman JP**, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2007; **13**: 367-371 [PMID: 17206695 DOI: 10.1002/ibd.20074]

102 **Jess T**, Loftus EV, Velayos FS, Winther KV, Tremaine WJ, Zinsmeister AR, Scott Harmsen W, Langholz E, Binder V, Munkholm P, Sandborn WJ. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. *Am J Gastroenterol* 2007; **102**: 829-836 [PMID: 17222314 DOI: 10.1111/j.1572-0241.2007.01070.x]

103 **Tung BY**, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. *Ann Intern Med* 2001; **134**: 89-95 [PMID: 11177311 DOI: 10.7326/0003-4819-134-2-200101160-00008]

104 **Sjöqvist U**, Tribukait B, Ost A, Einarsson C, Oxelmark L, Löfberg R. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. *Anticancer Res* 2004; **24**: 3121-3127 [PMID: 15510599]

105 **Pardi DS**, Loftus EV, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. *Gastroenterology* 2003; **124**: 889-893 [PMID: 12671884 DOI: 10.1053/gast.2003.50156]

106 **Bansal P**, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. *Am J Gastroenterol* 1996; **91**: 44-48 [PMID: 8561142]

107 **Rutter MD**, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. *Gastroenterology* 2006; **130**: 1030-1038 [PMID: 16618396 DOI: 10.1053/j.gastro.2005.12.035]

**P-Reviewer:** Christodoulidis G, Huang ZH, Manguso F, Nayak BS, Serafino A **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 risk of developing colorectal cancer in patients with ulcerative colitis**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** |  | **Years after UC** | | | |  |  | **Country** |
|  | 10 | 15 | 20 | 25 | 30 | 40 |  |
| Gilat *et al*[[14](#_ENREF_14)] | 1988 | 0.2% | 2.8% | 5.5% |  | 13.5% |  |  | Israel |
| Lennard-Jones *et al*[[13](#_ENREF_13)] | 1990 |  | 3% | 5% |  |  |  |  | United Kingdom |
| Langholz *et al*[[7](#_ENREF_7)] | 1992 |  |  |  | 3.1% |  |  |  | Denmark |
| Eaden *et al*[[9](#_ENREF_9)] | 2001 | 1.6% |  | 8.3% |  | 18.4% |  |  | United Kingdom |
| Hata *et al*[[22](#_ENREF_22)] | 2003 | 0.5% |  | 4.1% |  | 6.1% |  |  | Japan |
| Winther *et al*[[18](#_ENREF_18)] | 2004 | 0.4% |  | 1.1% |  | 2.1% |  |  | Denmark |
| Lakatos *et al*[[17](#_ENREF_17)] | 2006 | 0.6% |  | 5.4% |  | 7.5% |  |  | Hungary |
| Rutter *et al*[[107](#_ENREF_108)] | 2006 |  |  | 2.5% |  | 7.6% | 10.8% |  | United Kingdom |
| Soderlund *et al*[[20](#_ENREF_20)] | 2009 | 1% |  | 1.5% |  | 2.7% |  |  | Sweden |

UC: ulcerative colitis.

**Table 2 Timing of surveillance colonoscopy for colorectal cancer in ulcerative colitis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Guidelines** | **Beginning of surveillance (years after onset of symptoms)** | **Surveillance schedule** |
| Van Assche *et al*[[73](#_ENREF_73)] | 2013 | European Crohn’s and Colitis Organization (ECCO) | 8 yr | High risk1; 1-2 yr |
|  |  |  |  | Low risk1; 3-4 yr |
|  |  |  |  |  |
| Farraye *et al*[[72](#_ENREF_72)] | 2010 | American Gastroenterological Association (AGA) | 8 yr | Extensive colitis or left-sided colitis; 1-2 yr |
|  |  |  |  | Patients with PSC; 1 yr |
|  |  |  |  | High-grade or low-grade dysplasia; colectomy or repeat colonoscopy within 6 mo |
|  |  |  |  | Indifinite dysplasia; 3 to 12 mo |
|  |  |  |  | No dysplasia; 1-2 yr |
|  |  |  |  |  |
| Kornbluth *et al*[[70](#_ENREF_70)] | 2010 | American College of Gastroenterology (ACG) | 8-10 yr | 1-2 yr |
|  |  |  |  |  |
| Cairns *et al*[[68](#_ENREF_68)] | 2010 | British Society of Gastroenterology (BSG) | 10 yr | lower risk2; 5 yr |
|  |  |  |  | intermediate risk3; 3 yr |
|  |  |  |  | higher risk4; 1 yr |
|  |  |  |  |  |
| Leighton *et al*[[69](#_ENREF_69)] | 2006 | American Society for Gastrointestinal Endoscopy (ASGE) | 8-10 yr | 1-2 yr  (indefinite dysplasia: 3 to 6 mo) |
|  |  |  |  |  |
| Eaden *et al*[[71](#_ENREF_71)] | 2002 | United Kingdom | 8-10 years (pancolitis) | 3 yr (second decade) |
|  |  |  | 15-20 yr (left-sided colitis) | 2 yr (third decade) |
|  |  |  |  | 1 yr (fourth decade) |

1Low-risk is 0–2 points and high-risk is 3–4 points; risk factor: pancolitis, endoscopic and/or histological inflammation, pseudopolyps, and family history of CRC: each risk factor is counted with one point; 2Lower risk: extensive colitis with no active inflammation or left-sided colitis; 3Intermediate risk: extensive colitis with mild active inflammation or post-inflammatory polyps or family history CRC in FDR aged ≥ 50; 4Higher risk: active inflammation or stricture in past 5 years or dysplasia in past 5 years declining surgery or PSC/transplant for PSC or family history CRC in FDR aged < 50. PSC: primary sclerosing cholangitis; CRC: colorectal cancer; FDR: First-degree relatives.